In a 62‑year‑old patient with HIV on bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) who has osteoporosis and is already taking vitamin D but cannot take calcium supplements due to interaction concerns, what osteoporosis medication can be recommended that will not interact with Biktarvy?

Recommended Osteoporosis Treatment for HIV Patient on Biktarvy

Bisphosphonates, specifically alendronate (weekly oral) or zoledronic acid (yearly IV), are the recommended first-line osteoporosis medications for this patient, as they have no clinically significant interactions with Biktarvy and have proven efficacy in reducing fracture risk in HIV-infected patients. 1

Why Bisphosphonates Are the Answer

Bisphosphonates are explicitly recommended as first-line therapy for osteoporosis in HIV-infected patients 1. Both alendronate and zoledronic acid have been evaluated in 48-week randomized controlled trials specifically in HIV-infected patients, showing effects on bone mineral density and tolerability similar to the general population 1. Recent network meta-analysis data from 2025 confirms that zoledronate-based regimens significantly improve both lumbar spine BMD (0.0821-0.0985 g/cm²) and total hip BMD (0.0372-0.0606 g/cm²) in people living with HIV 2.

No Drug Interaction Concerns

Critically, the FDA label for Biktarvy does not list bisphosphonates as having any drug-drug interactions 3. The Biktarvy label explicitly states that no clinically significant drug interactions have been observed with multiple medications tested, and bisphosphonates are notably absent from the interaction tables 3.

Addressing the Calcium Misconception

You can actually give calcium supplements with Biktarvy—the interaction is manageable, not absolute. The FDA label specifies that Biktarvy and calcium-containing supplements can be taken together with food 3. The restriction only applies to fasting conditions. Specifically:

• With food: Biktarvy and calcium supplements can be taken together without timing restrictions
• Without food: Biktarvy should be taken at least 2 hours before or 6 hours after calcium supplements

This is a chelation-type interaction where calcium binds to bictegravir, reducing its absorption by approximately 33% under fasted conditions 4. However, food mitigates this interaction effectively 4.

Practical Treatment Algorithm

First-Line Options:

1. Alendronate 70 mg weekly (oral)

   • Reduces vertebral and hip fractures 1
   • Take on empty stomach with water, remain upright 30 minutes
   • No interaction with Biktarvy

2. Zoledronic acid 5 mg yearly (IV)

   • Superior BMD improvements in HIV patients 2
   • Highest treatment rankings (SUCRA: 93.2% for lumbar spine, 87.4% for total hip) 2
   • Consider for patients with poor oral medication adherence or GI intolerance
   • No interaction with Biktarvy

Essential Adjunctive Therapy:

• Continue vitamin D (already prescribed)
• Add calcium supplementation: 1000-1200 mg daily, taken with food and Biktarvy to avoid interaction 3
• Calcium and vitamin D are recommended as adjuncts to osteoporosis therapies 5

Important Clinical Considerations

Before starting bisphosphonates:

• Ensure vitamin D deficiency is corrected (25(OH)D >32 ng/mL) to prevent bisphosphonate-related hypocalcemia and maximize efficacy 1
• Complete any needed dental work first—osteonecrosis of the jaw risk is very rare (<1 per 100,000 person-years) but associated with recent dental procedures 1

Monitoring:

• Check BMD by DXA at spine and hip every 1-3 years to assess treatment response 5
• Consider bone turnover markers (C-terminal crosslinking telopeptide) as alternative monitoring 5

Duration considerations:

• Given the patient's age (62) and expected long lifespan with HIV, some experts recommend reassessing after 5 years of bisphosphonate therapy due to concerns about long-term bone turnover suppression 1
• However, 10-year data with alendronate shows continued BMD increases without increased fracture risk 1

Why Not Other Options?

• Denosumab: No interaction data provided, but bisphosphonates have more established evidence in HIV populations
• Raloxifene/SERMs: Only reduce vertebral fractures, not hip fractures—inferior for this patient's needs 5
• Teriparatide/Abaloparatide: Reserved for very high-risk patients; no specific HIV data provided
• Hormone therapy: Not appropriate for this 62-year-old patient (recommended only if <60 years or <10 years post-menopause) 5

The bottom line: Start alendronate 70 mg weekly or zoledronic acid 5 mg yearly, add calcium 1000-1200 mg daily taken with food alongside Biktarvy, and continue vitamin D.